Dr. Masoud Mokhtarani has extensive experience in clinical development from bench to market with a focus on proof of concept, translational and early-stage development programs across multiple therapeutic areas including neurodegenerative disease, systemic sclerosis, genetic and inherited inborn errors of metabolism, idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis and pain. Previously, Dr. Mokhtarani served as chief medical officer of NeuroVia Inc. and Curzion Pharmaceuticals (acquired by Horizon), where he successfully built clinical development plans for X-linked adrenoleukodystrophy, adrenomyeloneuropathy and fibrotic diseases. In addition, Dr. Mokhtarani also served in executive clinical roles at Hyperion Therapeutics (acquired by Horizon), Limerick Neuroscience, Rinat Neuroscience (acquired by Pfizer) and Immune Tolerance Network. He is a co-inventor of multiple issued patents and an author or co-author of several peer-reviewed publications. Dr. Mokhtarani received an MD from University of Tehran and completed his clinical research Fellowship at the University of California, San Francisco.